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Loss of sensory hair cells from exposure to certain licit drugs (e.g., aminoglycoside
antibiotics, platinum-based chemotherapy agents) can result in permanent hearing loss.
Here we ask if allosteric activation of the hepatocyte growth factor (HGF) cascade via
Dihexa, a small molecule drug candidate, can protect hair cells from aminoglycoside
toxicity. Unlike native HGF, Dihexa is chemically stable and blood-brain barrier permeable.
As a synthetic HGF mimetic, it forms a functional ligand by dimerizing with endogenous
HGF to activate the HGF receptor and downstream signaling cascades. To evaluate Dihexa
as a potential hair cell protectant, we used the larval zebrafish lateral line, which possesses
hair cells that are homologous to mammalian inner ear hair cells and show similar
responses to toxins. A dose-response relationship for Dihexa protection was established
using two ototoxins, neomycin and gentamicin. We found that a Dihexa concentration of
1 µM confers optimal protection from acute treatment with either ototoxin. Pretreatment
with Dihexa does not affect the amount of fluorescently tagged gentamicin that enters
hair cells, indicating that Dihexa’s protection is likely mediated by intracellular events
and not by inhibiting aminoglycoside entry. Dihexa-mediated protection is attenuated by
co-treatment with the HGF antagonist 6-AH, further evidence that HGF activation is a
component of the observed protection. Additionally, Dihexa’s robust protection is partially
attenuated by co-treatment with inhibitors of the downstream HGF targets Akt, TOR and
MEK. Addition of an amino group to the N-terminal of Dihexa also attenuates the protective
response, suggesting that even small substitutions greatly alter the specificity of Dihexa
for its target. Our data suggest that Dihexa confers protection of hair cells through an
HGF-mediated mechanism and that Dihexa holds clinical potential for mitigating chemical
ototoxicity.
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INTRODUCTION
Hearing loss and vestibular dysfunction are some of the most
prevalent and debilitating disorders due to social isolation
resulting from sensory deprivation. Particularly among the
elderly, those with untreated hearing loss are less likely to
participate in social activities and more likely to report levels of
depression and anxiety (Bess et al., 1989; Knutson and Lansing,
1990). Hearing loss can result from excessive exposure to loud
noise, genetic factors, or exposure to certain licit drugs, termed
ototoxins, such as aminoglycoside antibiotics and platinum-
based chemotherapeutics like cisplatin (Fee, 1980; Rybak et al.,
2009). Due to their high efficacy, many ototoxins are still used
despite the risk of hearing loss. Aminoglycoside antibiotics
are still widely used for a variety of clinical applications.
For example, cystic fibrosis patients suffer from severe gram-
negative bacterial infections and are commonly prescribed the
aminoglycoside antibiotics amikacin or tobramycin, despite as
high as a 14% incidence of hearing loss (Cheng et al., 2009).
Cisplatin use carries an even higher reported incidence of hearing
loss, between 28–68%, but it is used to treat several types
of soft tissue tumors and is the most commonly prescribed
chemotherapeutic for ovarian cancer (Rybak, 2007; Musial-Bright
et al., 2011).
The primary cellular basis for ototoxic hearing loss is
the death of sensory hair cells within the cochlea. Hair cells
are mechanosensitive receptors in the inner ear that detect
sounds and head movements; in mammals, loss of these cells is
permanent and irreversible. There are currently no food and drug
administration (FDA) approved treatments for the prevention
of toxin-induced hair cell loss. Identification of a preventative
therapy would allow for continued use of these efficacious
antibiotics and chemotherapeutics without the devastating
ototoxic consequences that accompany their use. Our work
identifies a new otoprotective drug that is already designed
for the clinical environment, allowing for quick transition to
clinical use.
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Studies involving acoustic and chemical insults show that
growth factors represent a compelling class of otoprotective
compounds (Yagi et al., 1999; Shoji et al., 2000; Kawamoto
et al., 2003; Liu et al., 2008). Hepatocyte growth factor (HGF),
a potent neurotrophic factor, affects a variety of neuronal
cell types to promote axon guidance and cell survival (Ebens
et al., 1996; Miyazawa et al., 1998). Direct application of
exogenous HGF onto cochlear explants protects hair cells from
neomycin ototoxicity (Kikkawa et al., 2009). However, HGF
itself does not represent a viable preventative therapeutic due
to low blood-brain barrier permeability and a half-life of
only 3.8 min (Appasamy et al., 1993). One study attempted
to circumvent these constraints by using viral HGF gene
delivery to the inner ear to drive constitutive HGF expression
(Oshima et al., 2004). This viral HGF gene delivery approach
protected rat cochlear hair cells from kanamycin ototoxicity,
further evidence for a protective role of HGF in the auditory
periphery. Unfortunately, viral gene therapy presents the risk
of insertional mutagenesis and does not reliably yield high
expression profiles (Monahan and Samulski, 2000). However,
development of a small molecule capable of stimulating
HGF, and its associated receptor c-Met, may be clinically
efficacious.
The HGF mimetic Dihexa is a synthetically derived
Angiotensin IV analog that is blood-brain barrier permeable,
stable, and orally bioavailable (McCoy et al., 2013). McCoy et al.
(2013) found that Dihexa treatment ameliorated memory loss
in a rat model of Parkinson’s Disease. Dihexa can bind to and
dimerize HGF, forming a functional ligand and thereby activating
c-Met (Benoist et al., 2014). HGF signaling is linked to neural
protection in rodents both in vitro and in vivo, making a strong
case for a small molecule activator of HGF/c-Met to confer
a neuroprotective benefit (Zhang et al., 2000; Niimura et al.,
2006). Here, we examine the otoprotective effects of Dihexa in a
zebrafish model of chemical ototoxicity.
The experimental value of zebrafish as an animal model for
in vivo drug discovery has grown rapidly due to their ease of
assessment, large clutch size, and ability to recapitulate human
disease conditions (MacRae and Peterson, 2003). The larval
zebrafish lateral line is an especially tractable model for the
identification of compounds that prevent hair cell loss (Coffin
et al., 2010; Esterberg et al., 2013). The lateral line system of
teleost fishes is an externally located, mechanosensitive sensory
system used to detect vibrations in the aquatic environment
that aid in predator detection, prey avoidance, and schooling
behavior (Coombs et al., 1989). Hair cells of the lateral line are
structurally and functionally similar to those of the mammalian
inner ear and, perhaps more importantly, respond similarly
to toxins (Harris et al., 2003; Ou et al., 2007; Coffin et al.,
2013b). Previous drug discovery work in the larval zebrafish
lateral line identified the novel compound PROTO-1 that prevents
aminoglycoside-induced hair cell toxicity in rodent models in
vivo, demonstrating that otoprotective drug discovery in zebrafish
translates to mammalian systems (Owens et al., 2008; Rubel et al.,
2011).
In this study, we demonstrate that Dihexa protects lateral line
hair cells from aminoglycoside ototoxicity. Dihexa does not alter
the entry of aminoglycosides into hair cells but rather attenuates
cell death through an HGF-dependent signaling mechanism.
This work demonstrates the potential clinical utility of Dihexa
as a co-administered protectant to prevent aminoglycoside
ototoxicity.
MATERIALS AND METHODS
ANIMALS
Larval zebrafish (∗AB) were obtained through pair-wise matings
and raised at 28.5◦C in petri dishes (Westerfield, 2000). All
zebrafish were maintained on a 14 h light/10 h dark cycle in
the Coffin Lab zebrafish facility at Washington State University,
Vancouver. Embryos were raised until 5 or 6 days post-
fertilization (dpf) prior to experimentation because larvae
younger than 5 dpf exhibit some resistance to aminoglycoside
ototoxicity (Murakami et al., 2003; Santos et al., 2006). Transgenic
Brn3c:mGFP zebrafish were used for direct hair cell counts and
c-Met localization studies. Brn3c:mGFP fish express membrane
bound GFP in hair cells under control of the Brn3c (aka Pou4f3)
promoter (Xiao et al., 2005). Previous work has demonstrated
that GFP positive cells in Brn3c:mGFP fish co-label with
phalloidin staining and thus can be used a reliable marker of
mature hair cells (Uribe et al., 2013). All experimental procedures
were approved by the Washington State University Animal Care
and Use Committee.
HGF RECEPTOR LOCALIZATION
Immunohistochemistry was performed using 1:500 anti-Met
(Cell Signaling, Danvers, MA). Following fixation in 4%
paraformaldehyde (PFA), 5 dpf Brn3c:mGFP larvae, which
express membrane-bound GFP in hair cells, were rinsed twice
with phosphate-buffered saline (PBS) for 10 min each and
then once with dH2o for 20 min. Larvae were then placed
into blocking solution, which consisted of 5% goat serum in
PBST (0.1% Triton x-100, Sigma) for 1 h. Fish were then
incubated overnight at 4◦C in anti-Met in PBST with 1%
goat serum. Excess primary antibody was washed off by three
10 min PBST rinses. Fish were then incubated for 4 h in 1:500
Alexa Fluor 568 secondary antibody (Life Technologies) diluted
in PBST at room temperature. Excess secondary antibody was
washed off by 3 consecutive 10-min rinses with PBST. Labeled
larvae were then rinsed once with PBS and stored in 1:1
PBS:glycerol for confocal imaging. Adult ∗AB liver was removed
and fixed for identical tissue processing (Gupta and Mullins,
2010).
DRUG TREATMENTS
Neomycin (10 mg/mL) and gentamicin (50 mg/mL) solutions
(Sigma-Aldrich; St. Louis, MO) were diluted in E2 embryo
medium (EM; 1 mM MgSO4, 120 µM KH2PO4, 74 µM
Na2HPO4, 1 mM CaCl2, 500 µM KCl, 15 mM NaCl, and 500 µM
NaHCO3 in dH2O; Westerfield, 2000) to working concentrations
of 25–400 µM. Cisplatin stock (1 mg/mL; WG Critical Care;
Paramus, NJ) was diluted in EM to working concentrations of
500–1000 µM and the pH adjusted to 7.2, since the cisplatin
stock is highly acidic. Dihexa was synthesized by RS Synthesis
(Louisville, KY) with a purity of 95.1%.
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Free swimming zebrafish larvae were placed in 6-well plates
and exposed to ototoxin in the presence or absence of Dihexa.
Fish were pretreated with Dihexa or vehicle dimethyl sulfoxide
(DMSO) control for 1 h. Fish were then co-treated with Dihexa
or DMSO and neomycin (30 min), acute gentamicin (30 min),
chronic gentamicin (6 h), or cisplatin (4 h). Ototoxin exposure
times were selected based on previous work (Ou et al., 2007;
Coffin et al., 2009; Owens et al., 2009). Fish were then rinsed three
times in EM. Gentamicin (chronic) and cisplatin exposed groups
and associated controls were assessed immediately following
the three EM washes. Fish treated acutely with neomycin or
gentamicin, and their associated controls, were allowed to recover
in EM for 45 min prior to hair cell assessment.
HAIR CELL ASSESSMENT
Survival of lateral line hair cells was assessed by vital dye
labeling in live fish. The vital dye 2-(4-(dimethylamino)styryl)-
N-ethylpyridinium iodide (DASPEI) (Life Technologies, Grand
Island, NY) is a marker of mitochondrial membrane potential
and preferentially stains lateral line hair cells when added to the
surrounding EM (Harris et al., 2003). Fish were incubated in
0.005% DASPEI for 15 min, then rinsed twice with EM and
anesthetized with 0.001% MS-222 (Argent Labs, Redmond, WA).
Using a Leica M165FC fluorescence dissection scope, 10 anterior
neuromasts (IO1, IO2, IO3, IO4, M2, MI1, MI2, O2, SO1, and
SO2; see Raible and Kruse, 2000) per fish were assessed based
on fluorescent intensity (Harris et al., 2003; Coffin et al., 2009;
Owens et al., 2009). An intensity score of 2 signifies intense
neuromast fluorescence, an intermediate score of 1 represents
faint DASPEI labeling, while a 0 neuromast score equates to
the absence of neuromast fluorescence at a given neuromast’s
stereotyped position. The scores from 10 neuromasts for each
fish were summed such that each larva receives a final score
between 0 (no neuromast fluorescence) and 20 (full complement
of hair cells in all 10 neuromasts). To obtain direct hair cell counts
from Brn3c:mGFP fish, we fixed larvae post-treatment in 4% PFA
overnight at 4◦C. Fish were rinsed with PBS three times, placed
in 1:1 PBS:glycerol, and mounted on bridged coverslips. Hair cell
counts for 5 anterior neuromasts (IO1, IO2, IO3, M2, and OP1)
per fish were obtained and summed.
AMINOGLYCOSIDE UPTAKE
Gentamicin conjugated to the fluorophore Texas Red (GTTR) was
used to determine if Dihexa affected aminoglycoside uptake by
hair cells (Steyger et al., 2003). Larvae were pretreated with Dihexa
or DMSO for 1 h, then co-treated with GTTR for 3 min, rinsed
4 times in EM for 30 s each, and fixed in 4% PFA overnight at 4◦C
(Owens et al., 2008). GTTR-labeled neuromasts were visualized
using a Leica SP8 confocal microscope, keeping gain and laser
intensity values constant for a given experiment. Z-stack images
of O2, MI1, and MI2 neuromasts were collected and compressed
using Leica LAS AF software. Neuromasts were masked using
a line tool and mean fluorescence was measured for an entire
neuromast using ImageJ version 1.48 (National Institutes of
Health, Bethesda, MD), mean background fluorescence was
then subtracted out to yield net mean fluorescence for each
neuromast.
PHARMACOLOGICAL INHIBITORS
Pharmacological inhibition of HGF/c-Met or its downstream
targets was used to elucidate which factors are important
for Dihexa-mediated otoprotection. All inhibitors used were
co-administered with Dihexa, that is 1 h pretreatment and
co-treatment with a given ototoxin. 6-AH is a metabolically
stable antagonist to the HGF/c-Met system that works by
preventing HGF dimerization and activation (Kawas et al., 2012).
We used 1 µM 6-AH as this concentration did not affect
fish health or alter hair cell loss in response to neomycin
but did attenuate neomycin-induced hair cell death. We used
10 µM rapamycin, a TOR inhibitor, (GenDEPOT, Barker, TX)
as this concentration had no affect on neomycin ototoxicity
or fish health but attenuated Dihexa hair cell protection in
preliminary experiments. Rapamycin concentrations as high
as 50 µM were tested initially and no overall toxicity was
observed. We conducted similar optimization experiments with
the MEK inhibitor, UO126 and an Akt inhibitor (CAS 612847-
09-3; both inhibitors from EMD Millipore, Billerica, MA),
selecting 1 µM as the optimal concentration of each compound.
For both UO126 and Akt inhibitor, the highest concentration
tested was 10 µM and we observed no overt toxicity at this
concentration.
STATISTICAL ANALYSIS
Data were analyzed using GraphPad Prism (V. 6.0, La Jolla,
CA). Statistical analyses were performed using either an
un-paired t-test assuming equal variance, one-, or two-way
ANOVA, as appropriate, and are specifically indicated on each
figure legend. Post hoc comparisons were performed using
Bonferonni corrections. Statistical values for ototoxin were
omitted from figure legends because it is established that they
cause a dose-dependent decrease in hair cell survival, in other
words, we know that a dose-response curve for neomycin
only will be statistically significant. All data are presented as
mean± s.e.m.
RESULTS
c-MET EXPRESSION IN LARVAL ZEBRAFISH NEUROMASTS
We immunohistochemically processed 5 dpf Brn3c:mGFP
larvae using anti-c-Met to determine if c-Met expression
is present in anterior lateral line neuromasts. In these fish,
GFP localizes to the hair cell membrane, allowing for easy
delineation of cell boundaries (Figure 1A). c-Met expression
was widespread in the skin epithelium, including in neuromasts
(red punctae in Figure 1B). No red punctae were present in
a secondary antibody only control that was not incubated in
anti-c-Met (Figures 1D–F). c-Met labeling is present both in
hair cells and in other cell types in the neuromast (Figure 1C).
To verify the validity of observed c-Met expression in hair
cells, adult ∗AB liver tissue was immunohistochemically
processed for anti-c-Met and DAPI (blue). c-Met expression
in the adult liver is widespread and punctate, similar
to the neuromast expression profile (Figure 1G). These
results indicate that our c-Met labeling is reliable and that
anterior lateral line neuromasts should be receptive to c-Met
modulation.
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FIGURE 1 | c-Met is expressed in lateral line neuromasts.
(A) Neuromast of a Brn3c:mGFP transgenic zebrafish with clearly labeled
hair cell boundaries. (B) Anti-c-Met labeling (red punctae) is present
throughout the neuromast. (C) Merged image shows c-Met is present near
the hair cell membrane and in surrounding cells. (D–F) Brn3c:mGFP larvae
incubated with secondary antibody only show no c-Met labeling. (G) ∗AB
adult liver tissue labeled with DAPI (blue) and anti-c-Met (red) demonstrates
robust, punctate c-Met expression. Scale bar in (C) represents 5 µm and
applies to images (A–F). Scale bar in (G) represents 5 µm.
DIHEXA PROTECTS LATERAL LINE HAIR CELLS FROM ACUTE
AMINOGLYCOSIDE TOXICITY
Treatment with Dihexa confers protection from neomycin in a
dose-dependent manner (Figure 2A). Untreated controls labeled
with the vital dye DASPEI display bright neuromast fluorescence
(Figure 2A inset). In contrast, animals treated with 200 µM
neomycin for thirty minutes exhibit dim or completely absent
fluorescence. The greatest protection was found at 10−6 M
(1 µM), where only a minor decrease from control hair cell
survival scores was observed. An additional peak of protection
was seen at 10−13 M (100 fM) but was inconsistent across
experiments, so all additional experiments were run with 10−6 M
(1 µM) Dihexa. Figure 2B shows that 10−6 M (1 µM) Dihexa
significantly protects hair cells from a range of neomycin
concentrations. Additionally, there was no observed toxicity of
Dihexa treatment alone. Dihexa also protects hair cells from
variable concentrations of acute gentamicin (Figure 2C).
Previous work has demonstrated that aminoglycosides activate
acute and slow (chronic) mechanisms that are distinct from one
another, with neomycin only activating acute mechanisms
but gentamicin activating both pathways (Coffin et al., 2009,
2013b; Owens et al., 2009). To ask if Dihexa can modulate
both mechanisms of aminoglycoside-induced hair cell death,
Dihexa pretreatment was followed by 6 h chronic gentamicin
co-treatment. Dihexa was not protective against chronic
gentamicin exposure (Figure 2D). Since slow-acting cell death
processes can proceed following ototoxin removal (Owens
et al., 2009), we next asked if Dihexa-mediated protection was
still present 6 h after neomycin exposure. Dihexa-mediated
protection was still robust 6 h post-neomycin washout (data not
shown).
To verify DASPEI scores, fish from the same treatment groups
were fixed and immunohistochemically processed with anti-
parvalbumin (Millipore) to visualize hair cells (see Coffin et al.,
2013b for details) (data not shown). Direct hair cell counts
were also obtained from Brn3c:mGFP fish, further demonstrating
that Dihexa robustly protects hair cells from neomycin damage
(Figure 3).These results indicate that Dihexa only modulates
targets responsible for the acute phase of aminoglycoside
ototoxicity.
DIHEXA DOES NOT BLOCK GENTAMICIN UPTAKE INTO HAIR CELLS
Certain otoprotectants, namely those with quinolone rings, have
been observed to confer protection by blocking aminoglycoside
entry into hair cells instead of modulating cell death targets
(Ou et al., 2009, 2012). To test if Dihexa blocks aminoglycoside
uptake by hair cells, we quantified GTTR fluorescence either
with or without 1 µM Dihexa. GTTR uptake was not altered
in the presence of Dihexa, as seen in the qualitative examples
and quantitative fluorescence data shown in Figure 4. This result
indicates that Dihexa likely protects hair cells by modulating a cell
death target.
DIHEXA OTOPROTECTION IS MEDIATED BY HGF/C-MET SIGNALING
We used the pharmacological inhibitor 6-AH to investigate if the
observed protection conferred by Dihexa is actually mediated
by HGF/c-Met signaling. 6-AH blocks HGF dimerization and
thereby inhibits subsequent c-Met activation (Kawas et al., 2012).
Treatment with 6-AH alone does not alter hair cell survival in
response to neomycin (Figure 5A). Co-treatment of larvae with
6-AH and Dihexa completely attenuates the hair cell protection
conferred by Dihexa treatment (Figure 5B). This observation
implicates the requirement of an active HGF/c-Met signal in
Dihexa otoprotection.
DOWNSTREAM CELLULAR MEDIATORS OF DIHEXA PROTECTION
Activation of the receptor tyrosine kinase c-Met leads to
the recruitment of many signaling mediators and ultimately
the activation of downstream signals, most notably Akt-
TOR and Ras-ERK (Organ and Tsao, 2011). The MAPK and
Akt inhibitors, UO126 and Akt inhibitor VIII respectively,
were used to determine to what extent, if any, activation
of their targets is required for Dihexa-mediated protection.
Optimal concentrations of UO126 and Akt Inhibitor VIII
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FIGURE 2 | Dihexa protects hair cells from acute aminoglycoside
treatment. (A) Dihexa confers dose-dependent protection from 200 µM
neomycin with two peaks of protection at 10−6 M (1 µM) and 10−13 M
(100 fM), with six concentrations of Dihexa providing significant
protection (One-way ANOVA; F (9,70) = 20.53 p < 0.001). Control fish
exposed to embryo medium (EM) only (inset top) and 1 µM Dihexa plus
200 µM neomycin (inset bottom) display bright DASPEI fluorescence
while fish treated with 200 µM neomycin alone (inset middle) display dim
to absent DASPEI fluorescence. Scale bar represents 250 µm and applies
to all three images in (A). (B) 1 µM Dihexa provides robust protection
from aminoglycoside treatment across multiple concentrations of
neomycin (Two-way ANOVA; Dihexa: F (1,63) = 155.8 p < 0.001). (C) 1 µM
Dihexa confers significant protection from acute gentamicin exposure
across all concentrations of gentamicin tested (Two-way ANOVA; Dihexa:
F (1,71) = 58.42 p < 0.001). (D) 1 µM Dihexa does not provide protection
against chronic gentamicin exposure (Two-way ANOVA; Dihexa:
F (1,81) = 1.458 p > 0.05). Asterisks indicate significant difference from
aminoglycoside only control (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005,
∗∗∗∗p < 0.001). N = 7–11 animals per treatment, error bars
represent ± s.e.m.
(1 µM) were determined based on the highest concentration
of each compound that did not shift the neomycin dose-
response curve (data not shown). At neomycin concentrations
of 100, 200, and 400 µM either inhibitor demonstrated partial
attenuation of Dihexa otoprotection, indicating at least partial
reliance on their associated signaling proteins for protective
effects (Figure 6A). Interestingly, when both inhibitors are
co-administered the result is similar to each administered
independently, suggesting that other signaling proteins may also
contribute to protection (data not shown). Phosphorylation
of Akt leads to activation of TOR, a molecular sensor of
metabolism and cellular homeostasis (Wullschleger et al., 2006).
We used the TOR inhibitor rapamycin to determine the
extent to which activation of TOR is required in Dihexa-
mediated protection. 10 µM rapamycin alone did not affect
the neomycin dose-response curve (Figure 6B). However, co-
treatment with 1 µM Dihexa and 10 µM rapamycin showed
significant attenuation of hair cell protection at 50 and
100 µM neomycin. From these results we hypothesize that
Dihexa-mediated protection relies, at least in part, on the
activation of multiple downstream targets of the HGF/c-Met
system (Akt-TOR and Ras-ERK).
MODIFIED DIHEXA IS NOT A HAIR CELL PROTECTANT
To test the specificity of Dihexa for the observed protection, we
synthesized an additional Dihexa variant that was missing an N-
terminal amino group. We tested the modified Dihexa against
200 µM neomycin and observed no protection, suggesting that
the current form of Dihexa has a high specificity for providing
protection, likely via its specific interaction with native HGF
(Figure 7).
DIHEXA DOES NOT PROTECT HAIR CELLS FROM CISPLATIN
Previous work with chemical and genetic cell death modulators
suggests that cisplatin and aminoglycosides share some cell death
pathways while also activating a distinct subset of signaling
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FIGURE 3 | Dihexa treatment prevents neomycin-induced hair cell loss
in Brn3c:mGFP transgenic larvae. (A) DMSO-treated control, (B) 400 µM
neomycin treated neuromast shows a reduction in hair cells, and
(C) neuromasts treated with 1 µM Dihexa plus 400 µM neomycin remain
mostly intact. (D) 1 µM Dihexa provides protection from neomycin-induced
hair cell loss across the neomycin dose-response curve (Two-way ANOVA;
Dihexa: F (1,456) = 50.77 p < 0.001). Asterisks indicate significant difference
from neomycin control (∗∗p < 0.01, ∗∗∗∗p < 0.001). N = 8–10 animals per
treatment, error bars represent ± s.e.m.
FIGURE 4 | Dihexa does not block aminoglycoside entry into hair cells.
There was no significant difference in quantified GTTR fluorescence within
neuromasts of animals treated with or without 1 µM Dihexa (t-test;
p = 0.1158). Sample control neuromast with bright GTTR fluorescence
(inset top) is qualitatively the same intensity as a neuromast treated with
1 µM Dihexa (inset bottom). Scale bar represents 10 µm and applies to
both images. N = 8 animals per treatment, error bars represent ± s.e.m.
pathways (Owens et al., 2008; Vlasits et al., 2012; Coffin et al.,
2013b). Animals exposed to Dihexa exhibit no shift in the
cisplatin dose-response curve (Figure 8). This result signifies
that Dihexa’s protection is likely by mediating the response
of an aminoglycoside-specific target that is not shared by
cisplatin.
FIGURE 5 | Dihexa-mediated protection is inhibited by the HGF
antagonist 6-AH. (A) Treatment with 1 µM 6-AH does not alter lateral
line hair cell survival in response to neomycin (Two-way ANOVA; 6-AH:
F (1,72) = 3.255 p = 0.0754). (B) Treatment with 1 µM Dihexa decreases
neomycin-induced hair cell death over multiple concentrations of neomycin.
Co-treatment with 6-AH completely attenuates Dihexa-mediated protection
(Two-way ANOVA; Dihexa: F (2,76) = 76.30 p < 0.001). There is a significant
difference (p < 0.001) when comparing 1 µM Dihexa vs. 1 µM Dihexa plus
1 µM 6-AH at 50, 100, and 200 µM neomycin treatment groups, p < 0.05
at 400 µM neomycin. N = 6–9 animals per treatment, error bars represent
± s.e.m.
DISCUSSION
We show that the HGF mimetic Dihexa protects lateral line
hair cells from acute aminoglycoside ototoxicity. Previous
work has reported that HGF/c-Met activation can confer hair
cell protection from aminoglycoside damage, consistent with
our results (Monahan and Samulski, 2000; Oshima et al.,
2004; Kikkawa et al., 2009). However, the innate chemical
properties of HGF, such as a short half-life, make it a poor
therapeutic option (Appasamy et al., 1993). Additionally, HGF
synthesis is prohibitively expensive, similar to other protein-
derived neurotrophic factors (Swartz, 2001). These obstacles
can be overcome by Dihexa, a synthetic, small molecule
HGF mimetic that is orally bioavailable, metabolically stable,
blood-brain barrier permeable, and inexpensive to synthesize
(McCoy et al., 2013). Treatment with Dihexa has been shown
to reliably activate c-Met activity through HGF-dependent
interactions (Benoist et al., 2014). We think Dihexa represents
an exciting new drug candidate for attenuating aminoglycoside
ototoxicity.
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FIGURE 6 | Dihexa-mediated protection is inhibited by MEK, Akt, and
TOR inhibitors. (A) Co-treatment with 1 µM MEK or Akt inhibitors (UO126
and Akt Inhibitor VIII, respectively) partially attenuates Dihexa-dependent
protection (Two-way ANOVA; Dihexa: F (3,144) = 37.13 p < 0.001). When
comparing the 1 µM Dihexa treatment vs. 1 µM Dihexa plus 1 µM UO126
p-values are as follows: 50 µM neomycin (p < 0.05), 100 µM neomycin
(p < 0.05), 200 µM neomycin (p < 0.001), and 400 µM neomycin
(p < 0.05). When comparing the 1 µM Dihexa treatment vs. 1 µM Dihexa
plus 1 µM Akt inhibitor VIII p-values are as follows: 50 µM neomycin
(p > 0.05), 100 µM neomycin (p < 0.05), 200 µM neomycin (p < 0.001),
400 µM neomycin (p > 0.05). (B) Co-treatment with 10 µM of the TOR
inhibitor, rapamycin, also partially attenuates Dihexa-mediated protection
from neomycin (Two-way ANOVA; Dihexa: F (3,120) = 70.41 p < 0.001).
When comparing the 1 µM Dihexa treatment vs. 1 µM Dihexa plus 10 µM
rapamycin p-values were as follows: 50 µM neomycin (p < 0.001), 100 µM
neomycin (p < 0.001), 200 and 400 µM neomycin (p > 0.05). N = 6–9
animals per treatment, error bars represent ± s.e.m.
Attenuation of aminoglycoside-induced hair cell death can
result from two mechanistic categories: blockage of aminogly-
coside uptake by hair cells or modulation of intracellular
signaling pathways. Functional mechanotransduction is a known
requirement for aminoglycoside entry into hair cells and its
resulting ototoxicity (Alharazneh et al., 2011; Vu et al., 2013).
Some compounds that protect hair cells from aminoglycoside
exposure, for example tacrine and other quinoline ring-
containing structures, do so by inhibiting aminoglycoside
uptake (Ou et al., 2009, 2012). Even compounds with
known intracellular targets, such as the estrogen receptor
modulator raloxifene, may protect hair cells by inhibiting
aminoglycoside entry, rather than acting via modulation of
estrogen signaling (Vlasits et al., 2012). Here, we measured
FIGURE 7 | A Dihexa variant that is missing an N-terminal amino group
(modified) does not provide protection against 200 µM neomycin.
1 µM Dihexa provides robust protection from 200 µM neomycin (t-test;
p < 0.001) whereas 1 µM of modified Dihexa provides no significant
protection (p = 0.34) when compared to 200 µM neomycin. Asterisks
indicate significant difference from 200 µM neomycin control
(∗∗∗∗p < 0.001). N = 7 animals per treatment, error bars represent ± s.e.m.
FIGURE 8 | Dihexa confers no protection from cisplatin ototoxicity.
Cisplatin dose-response curves with and without dihexa are nearly identical
(Two-way ANOVA; Dihexa: F (1,39) = 0.1845 p = 0.6699). N = 5–7 animals
per treatment, error bars represent ± s.e.m.
no difference in aminoglycoside uptake in hair cells treated
with or without Dihexa, suggesting that Dihexa confers
protection by modulation of cellular targets rather than blocking
aminoglycoside uptake.
HGF/c-Met activates a diverse set of signal transducers capable
of inhibiting cell death. For example, in various cell culture lines,
c-Met phosphorylation can result in downstream activation of
Akt, Erk/MAPK, JNK, or FAK signaling (reviewed by Organ
and Tsao, 2011). We found that Dihexa-mediated protection
requires activation of Akt, TOR, and MEK signaling, as inhibition
of any of these targets attenuates Dihexa-mediated protection.
Similarly, Insulin-like growth factor 1 hair cell protection from
neomycin damage is lost by inhibition of Akt or MEK signaling,
suggesting that growth factor otoprotection may operate on
a similar set of downstream targets (Hayashi et al., 2013).
Endogenous Akt activation also plays a survival role in cochlear
hair cells in response to gentamicin ototoxicity (Chung et al.,
2006). Activation of Akt or MEK in cell culture can prevent
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proteolytic cleavage of pro-caspase-9 thereby inhibiting classical
caspase-dependent apoptosis (Cardone et al., 1998; Allan et al.,
2003). The necessity of caspase activation for aminoglycoside-
induced hair cell death is still debatable, so alternative, caspase-
independent pathways may lie downstream of Dihexa-mediated
protection (Cunningham et al., 2002; Matsui et al., 2003;
Jiang et al., 2006; Coffin et al., 2013b). The pro-survival
protein Bcl-2 regulates cell death by inhibiting pro-cell death
members of the Bcl-2 family of proteins (Reviewed by Czabotar
et al., 2014). Both HGF application and Akt activity result in
increased Bcl-2 expression in cell culture (Pugazhenthi et al.,
2000; Gordin et al., 2010). In human endothelial cells, HGF-
induced cellular protection from hypoxia is dependent on Bcl-2
activity (Yamamoto et al., 2001). Bcl-2 overexpression protects
hair cells from aminoglycoside exposure both in vitro and
in vivo (Cunningham et al., 2004; Pfannenstiel et al., 2009;
Coffin et al., 2013a). Given the complexity of signal modulators
downstream of HGF/c-Met, additional work is needed to better
understand what processes are important for Dihexa’s hair cell
protection.
Understanding hair cell death mechanisms activated by
specific ototoxins can help shed light on what molecular
signals to therapeutically target for each toxic agent. Dihexa
treatment protected hair cells from acute aminoglycoside
treatment (neomycin or gentamicin) but conferred no protection
from chronic gentamicin or cisplatin exposure. These data are
consistent with known differences in cell death signals activated
across these three groups (cisplatin, acute aminoglycosides, and
chronic aminoglycosides). There are at least two processes of
aminoglycoside-induced cell death that depend on both the
particular aminoglycoside and exposure time (Coffin et al., 2009;
Owens et al., 2009). Pharmacological inhibition of Bax, a Bcl-2
family member that promotes cell death, prevents neomycin but
not gentamicin ototoxicity in zebrafish (Coffin et al., 2013a,b).
In contrast, inhibition of p53 protects lateral line hair cells from
acute neomycin or gentamicin as well as chronic gentamicin
exposure (Coffin et al., 2013a). A previously identified hair
cell protectant, PROTO1, showed robust protection from acute
aminoglycoside exposure but only modest protection from the
chronic process and offered no protection against cisplatin,
similar to the result demonstrated here with Dihexa (Owens
et al., 2008). Additionally, Vlasits et al. also identified multiple
compounds from a FDA-approved drug screen with very similar
protection profiles to Dihexa (Vlasits et al., 2012). These results
describe a system of aminoglycoside-induced cell death that both
shares molecular targets but also has unique features depending
on aminoglycoside and exposure time. Dihexa’s protection
from acute but not chronic aminoglycoside exposure further
strengthens the two-phase model of aminoglycoside induced-hair
cell death.
Future work will address the efficacy of Dihexa as a hair
cell protect in mammalian models and against additional
aminoglycosides. In summary, our study identifies a new hair
cell protectant, Dihexa, that relies upon HGF/c-Met signal
transduction for its protection. Due to its conscious design as
an orally bioavailable compound, Dihexa is a strong clinical
candidate as a hair cell protectant.
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